# FewerJobs export - 100 curated jobs
Generated: 2026-11-21T02:45:42.208Z
Source: https://fewerjobs.com

## Filters applied
- **q**: Summit Therapeutics
- **quality_floor**: all
- **match_401k_strict**: true
- **parental_strict**: true
- **non_birth_strict**: true
- **pto_strict**: true
- **include_older**: false
- **apply_url_verified**: false
- **page**: 1
- **per_page**: 100
- **sort**: relevance

## Jobs
### Corporate Counsel, Clinical Contracts - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $158K-$185K
- Posted: 2026-10-09
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4439287009
- Excerpt: Corporate Counsel, Clinical Contracts Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Director, Clinical Scientist - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $192K-$239K
- Posted: 2026-10-14
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4451017009
- Excerpt: Director, Clinical Scientist Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

### Senior Medical Director - Summit Therapeutics
- Location: remote (remote)
- Salary: $253K-$317K
- Posted: 2026-07-08
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4308546009
- Excerpt: Senior Medical Director remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy

### Director, Biostatistics - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $203K-$253K
- Posted: 2026-03-18
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4183442009
- Excerpt: Director, Biostatistics Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy

### Sr. Manager, Clinical Quality Assurance - Summit Therapeutics
- Location: Remote (remote)
- Salary: $158K-$185K
- Posted: 2026-09-09
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4394920009
- Excerpt: Sr. Manager, Clinical Quality Assurance Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Senior Legal Counsel - Summit Therapeutics
- Location: Princeton, NJ (unspecified)
- Salary: $203K-$243K
- Posted: 2026-10-16
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4452094009
- Excerpt: Senior Legal Counsel Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

### Chief Commercial Officer - Summit Therapeutics
- Location: Princeton, NJ (US) (unspecified)
- Salary: $400K-$480K
- Posted: 2026-09-05
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4396494009
- Excerpt: Chief Commercial Officer Princeton, NJ (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Associate Director, Medical Writing - Summit Therapeutics
- Location: remote (remote)
- Salary: $169K-$198K
- Posted: 2026-10-08
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4437581009
- Excerpt: Associate Director, Medical Writing remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

### Senior Director, Regulatory Affairs - Summit Therapeutics
- Location: (Remote US) (remote)
- Salary: $203K-$253K
- Posted: 2026-08-18
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4372636009
- Excerpt: Senior Director, Regulatory Affairs (Remote US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Associate Director, Regulatory Affairs - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $168K-$198K
- Posted: 2026-09-08
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4396736009
- Excerpt: Associate Director, Regulatory Affairs Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Manager, FP&A - Summit Therapeutics
- Location: Palo Alto, CA (unspecified)
- Salary: $139K-$163K
- Posted: 2026-10-19
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4452178009
- Excerpt: Manager, FP&A Palo Alto, CA About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

### Senior Director, Regulatory CMC - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $220K-$275K
- Posted: 2026-09-10
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4401397009
- Excerpt: Senior Director, Regulatory CMC Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Regional Medical Science Director (Northeast) - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $200K-$235K
- Posted: 2026-08-26
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4381637009
- Excerpt: Regional Medical Science Director (Northeast) Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

### Director, Regulatory Affairs CMC - Summit Therapeutics
- Location: Remote (remote)
- Salary: $190K-$237K
- Posted: 2026-10-21
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4450841009
- Excerpt: Director, Regulatory Affairs CMC Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

### Associate Director, Site Alliances and Strategy - Summit Therapeutics
- Location: Remote (remote)
- Salary: $169K-$198K
- Posted: 2026-10-20
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4450077009
- Excerpt: Associate Director, Site Alliances and Strategy Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

### Director, Strategic Analytics and Market Research - Summit Therapeutics
- Location: Princeton, NJ (unspecified)
- Salary: $203K-$253K
- Posted: 2026-11-18
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4510424009
- Excerpt: Director, Strategic Analytics and Market Research Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

### Director, Clinical Operations Analytics & Performance Excellence - Summit Therapeutics
- Location: Remote (remote)
- Salary: $190K-$237K
- Posted: 2026-10-13
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4448661009
- Excerpt: Director, Clinical Operations Analytics & Performance Excellence Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

### Associate Director, Clinical Data Management - Summit Therapeutics
- Location: Palo Alto, CA (unspecified)
- Salary: $174K-$205K
- Posted: 2026-10-08
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4436525009
- Excerpt: Associate Director, Clinical Data Management Palo Alto, CA About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

### Senior Manager, Clinical Pharmacology & DMPK - Summit Therapeutics
- Location: Palo Alto, California, United States (unspecified)
- Salary: $148K-$174K
- Posted: 2026-08-21
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4377983009
- Excerpt: Senior Manager, Clinical Pharmacology & DMPK Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

### Associate Director, CMC Statistics - Summit Therapeutics
- Location: Princeton, NJ (unspecified)
- Salary: $180K-$200K
- Posted: 2026-10-19
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4453207009
- Excerpt: Associate Director, CMC Statistics Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Associate Director, Clinical Supply Management - Summit Therapeutics
- Location: Princeton, NJ (US) and Palo Alto, CA (US) (unspecified)
- Salary: $174K-$204K
- Posted: 2026-10-14
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4451427009
- Excerpt: Associate Director, Clinical Supply Management Princeton, NJ (US) and Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared

### Associate Director, Clinical Pharmacology & DMPK - Summit Therapeutics
- Location: Palo Alto, California, United States (unspecified)
- Salary: $174K-$204K
- Posted: 2026-10-30
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4464644009
- Excerpt: Associate Director, Clinical Pharmacology & DMPK Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

### Associate Director, Scientific Publications - Summit Therapeutics
- Location: Palo Alto, California, United States (unspecified)
- Salary: $174K-$204K
- Posted: 2026-08-25
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4380731009
- Excerpt: Associate Director, Scientific Publications Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

### Senior Analyst (R&D Finance/Accounting) - Summit Therapeutics
- Location: Palo Alto, CA (US) (unspecified)
- Salary: $117K-$130K
- Posted: 2026-08-25
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4381042009
- Excerpt: Senior Analyst (R&D Finance/Accounting) Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

### Director, Value Outcomes Liaison (VOL) - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $190K-$237K
- Posted: 2026-08-25
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4380805009
- Excerpt: Director, Value Outcomes Liaison (VOL) Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

### Associate Director, CMC / Quality Project Management - Summit Therapeutics
- Location: Princeton, NJ (unspecified)
- Salary: $174K-$204K
- Posted: 2026-11-06
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4483207009
- Excerpt: Associate Director, CMC / Quality Project Management Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

### Director, Sourcing & Procurement - R&D Clinical Operations and Supplies - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $190K-$237K
- Posted: 2026-10-14
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4452526009
- Excerpt: Director, Sourcing & Procurement - R&D Clinical Operations and Supplies Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with

### Associate Director, Clinical Supply Management (UK/EU) - Summit Therapeutics
- Location: Oxford, UK, Zug Switzerland, Dublin Ireland (unspecified)
- Salary: GBP 83K-98K
- Posted: 2026-10-15
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4451559009
- Excerpt: Associate Director, Clinical Supply Management (UK/EU) Oxford, UK, Zug Switzerland, Dublin Ireland About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with

### Associate Director, Alliance & Business Operations - Summit Therapeutics
- Location: Palo Alto, California, United States (unspecified)
- Salary: $169K-$198K
- Posted: 2026-11-17
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4508999009
- Excerpt: Associate Director, Alliance & Business Operations Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

### Associate Director, Training & Education-Medical Affairs - Summit Therapeutics
- Location: Princeton, New Jersey, United States (unspecified)
- Salary: $174K-$204K
- Posted: 2026-08-12
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4363784009
- Excerpt: Associate Director, Training & Education-Medical Affairs Princeton, New Jersey, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

### Director, Medical Affairs Operations - Summit Therapeutics
- Location: Princeton, New Jersey, United States (unspecified)
- Salary: $190K-$237K
- Posted: 2026-10-23
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4462153009
- Excerpt: Director, Medical Affairs Operations Princeton, New Jersey, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

### Senior Clinical Trial Manager - Summit Therapeutics
- Location: Remote (remote)
- Salary: $158K-$185K
- Posted: 2026-11-05
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4452491009
- Excerpt: Senior Clinical Trial Manager Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

### Medical Writer, Medical Communications & Publications - Summit Therapeutics
- Location: Palo Alto, California, United States (unspecified)
- Salary: $145K-$185K
- Posted: 2026-10-24
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4462175009
- Excerpt: Medical Writer, Medical Communications & Publications Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

### Senior Manager, Externally Sponsored Research - Summit Therapeutics
- Location: Palo Alto, California, United States (unspecified)
- Salary: $158K-$185K
- Posted: 2026-10-22
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4462164009
- Excerpt: Senior Manager, Externally Sponsored Research Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

### Director, Portfolio Strategy - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $190K-$237K
- Posted: 2026-11-04
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4478975009
- Excerpt: Director, Portfolio Strategy Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

### IT Business Analyst - G&A - Summit Therapeutics
- Location: Palo Alto, CA (US) (unspecified)
- Salary: $98K-$128K
- Posted: 2026-08-31
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4388810009
- Excerpt: IT Business Analyst - G&A Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

### Head of European Market Access – Oncology (Solid Tumors) - Summit Therapeutics
- Location: International Template (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-05
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4479285009
- Excerpt: Head of European Market Access – Oncology (Solid Tumors) International Template About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

### Director, MSAT-Drug Product (US, UK, Ireland, or Switzerland) - Summit Therapeutics
- Location: Princeton, NJ (US) (unspecified)
- Salary: $203K-$253K
- Posted: 2026-10-29
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4467899009
- Excerpt: Director, MSAT-Drug Product (US, UK, Ireland, or Switzerland) Princeton, NJ (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

### Manager, Quality Assurance - Summit Therapeutics
- Location: Princeton, NJ (unspecified)
- Salary: $139K-$163K
- Posted: 2026-10-20
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4450807009
- Excerpt: Manager, Quality Assurance Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

### Sr. Clinical Data Scientist - Summit Therapeutics
- Location: Palo Alto, CA (unspecified)
- Salary: $148K-$188K
- Posted: 2026-09-10
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4401136009
- Excerpt: Sr. Clinical Data Scientist Palo Alto, CA About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

### Director, Clinical Operations Middle East - Summit Therapeutics
- Location: UAE (unspecified)
- Salary: Not disclosed
- Posted: 2026-07-16
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4320953009
- Excerpt: Director, Clinical Operations Middle East UAE About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Senior Medical Science Liaison (Mountain West) - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $200K-$235K
- Posted: 2026-08-26
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4381613009
- Excerpt: Senior Medical Science Liaison (Mountain West) Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

### Senior Director, Artificial Intelligence - Summit Therapeutics
- Location: Palo Alto, California, United States, Princeton, New Jersey, United States (unspecified)
- Salary: $217K-$271K
- Posted: 2026-08-04
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4354676009
- Excerpt: Senior Director, Artificial Intelligence Palo Alto, California, United States, Princeton, New Jersey, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy

### Clinical Supply Planning Manager - Summit Therapeutics
- Location: Princeton, NJ (unspecified)
- Salary: $139K-$142K
- Posted: 2026-10-16
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4456435009
- Excerpt: Clinical Supply Planning Manager Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Paralegal - Summit Therapeutics
- Location: Palo Alto, CA (US) (unspecified)
- Salary: $139K-$163K
- Posted: 2026-10-21
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4462904009
- Excerpt: Paralegal Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

### Head, National Field Medical - Summit Therapeutics
- Location: Remote (US) (remote)
- Salary: $306K-$382K
- Posted: 2026-11-10
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4487651009
- Excerpt: Head, National Field Medical Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an

### Head of Europe, Middle East & Africa (EMEA) - Summit Therapeutics
- Location: International Template (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-02
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4475952009
- Excerpt: Head of Europe, Middle East & Africa (EMEA) International Template About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

### Senior Manager of Technical QA (GMP) - Summit Therapeutics
- Location: Palo Alto, CA (US) (unspecified)
- Salary: $158K-$185K
- Posted: 2026-09-21
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4409827009
- Excerpt: Senior Manager of Technical QA (GMP) Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

### Senior Principal Scientist - Summit Therapeutics
- Location: Palo Alto, CA (US) (unspecified)
- Salary: $168K-$197K
- Posted: 2026-10-15
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4451700009
- Excerpt: Senior Principal Scientist Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is

### Senior Medical Science Liaison (IL, WI) - Summit Therapeutics
- Location: Chicago, Illinois, United States (unspecified)
- Salary: $200K-$235K
- Posted: 2026-10-07
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4434822009
- Excerpt: Senior Medical Science Liaison (IL, WI) Chicago, Illinois, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

### Clinical Trial Manager II - Summit Therapeutics
- Location: Oxford, England, Dublin, Ireland, Remote (remote)
- Salary: $67K-$79K
- Posted: 2026-11-06
- Apply: https://job-boards.greenhouse.io/summittherapeutics/jobs/4484742009
- Excerpt: Clinical Trial Manager II Oxford, England, Dublin, Ireland, Remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

### Associate Director, US Oncology, Treatment Site Operations Coordinator (TSOC) Lead - Merck & Co., Inc.
- Location: 2 Locations (unspecified)
- Salary: $157K-$247K
- Posted: 2026-11-12
- 401(k) match: listed (not source-backed)
- Apply: https://msd.wd5.myworkdayjobs.com/SearchJobs/job/USA---Pennsylvania---North-Wales-Upper-Gwynedd/Associate-Director--US-Oncology--Treatment-Site-Operations-Coordinator--TSOC--Lead_R415139
- Excerpt: Associate Director, US Oncology, Treatment Site Operations Coordinator (TSOC) Lead 2 Locations Job Description The U.S. Oncology business within our company is a growing and dynamic organization committed to advancing innovative therapies for patients with cancer. We have an exciting opportunity to join our dynamic commercial team as we prepare for the potential U.S. launch of an mRNA-based individualized neoantigen therapy for early-stage melanoma, being developed through an alliance partnership. This novel product has the potential to redefine personalized cancer treatment and requires a highly coordinated operating model to support seamless therapy delivery across a complex treatment ecosystem. Reporting to the Director, Individualized Therapy Operations, the Associate Director, Treatment Site Operations Coordinator (TSOC) Lead is responsible for leading the centralized operational coordination capability that supports execution of the Intismeran treatment journey. This leader will build, develop, and oversee a team of Treatment Site Operations Coordinators (TSOCs) responsible for coordinating patient cases, managing operational workflows, facilitating communication across stakeholders, and ensuring timely progression of patients through key treatment journey milestones. The role serves as the primary operational bridge between Treatment Site Leads (TSLs), treatment sites, alliance stakeholders, manufacturers, sequencing providers, pathology laboratories, distributors, patient support programs, and internal teams. The TSOC team functions as the centralized coordination hub for the treatment journey, providing operational visibility, issue resolution, stakeholder communication, and case-level support to ensure patients successfully progress through each stage of the individualized therapy process. This role is accountable for establishing consistent operational standards, escalation pathways, and ways of working that

### Nuclear Medicine Tech - CommonSpirit Health
- Location: UNAVAILABLE, UNAVAILABLE, UNAVAILABLE (unspecified)
- Salary: Not disclosed
- Posted: 2026-08-31
- 401(k) match: listed (not source-backed)
- Apply: https://careers-commonspirit.icims.com/jobs/490271/nuclear-medicine-tech/job
- Excerpt: Nuclear Medicine Tech UNAVAILABLE, UNAVAILABLE, UNAVAILABLE Where You'll Work St. Anthony Summit Hospital is a Level III trauma center serviced by Flight For Life® Colorado. We are nationally recognized as a multiple-time recipient of the Press Ganey Guardian of Excellence Award for Patient Experience, and we were named a Top 100 Hospital in the U.S. by IBM Watson Health in 2018. We also are a Pathway to Excellence-designated hospital, recognized by the American Nurses Credentialing Center as being one of the best hospitals for nurses to work. We provide a full range of medical specialties and health care services to Summit County and the surrounding region, including surgical, emergency/trauma, critical care, birth center, orthopedics, breast care, digital mammography, breast MRI, radiology and imaging, infusion therapy, nuclear medicine, cardiology, oncology, Summit Sleep Disorders Center, Ear Nose and Throat (ENT), gastroenterology and Total Joint Replacement. We proudly provide convenient care where you live, work and play - that's why visitors and residents alike can count on us for emergent and urgent medical services. In addition to 24/7, Level III emergency care at St. Anthony-Summit Hospital in Frisco, we have three emergency mountain clinics at the base of the Breckenridge, Copper Mountain and Keystone resorts, as well as urgent care and primary care available from CMG High Country Healthcare clinics in Frisco, Breckenridge and Silverthorne. Job Summary and Responsibilities As our Nuclear Medicine Tech, you will provide diagnostic and therapeutic nuclear medicine procedures for inpatients and outpatients through the administration of radiopharmaceuticals and

### Senior Director, Clinical Pharmacology - Rhythm Pharmaceuticals Inc
- Location: Location not specified (unspecified)
- Salary: $210K-$300K
- Posted: 2026-10-01
- 401(k) match: listed (not source-backed)
- Apply: https://rhythmpharmaceuticals.applytojob.com/apply/PWn97iW7T2/Senior-Director-Clinical-Pharmacology
- Excerpt: Senior Director, Clinical Pharmacology Company Overview Rhythm is a global, commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. We develop medicines for previously untreatable or undertreated diseases and provide meaningful support for healthcare providers and patients and their families. We recognize the courage it takes for patients and their caregivers to begin their journey of advocacy to find the answers they need. Their courage inspires us to challenge convention, ask bold questions and seek answers for them. Every day, we strive for excellence through our willingness to adapt, learn, and our tenacity to overcome barriers, together. Opportunity Overview Rhythm Pharmaceuticals is seeking a Senior Director, Clinical Pharmacology with demonstrable experience and expertise in early and late-phase clinical development of small molecule and peptide mono- and combination-therapy strategies to join our development team. The successful candidate will report to the CMO and play a critical leadership role in shaping and executing the clinical pharmacology strategy for programs targeting rare neuroendocrine diseases. This individual will serve as the company's clinical pharmacology subject matter expert, partnering closely with senior leadership to influence portfolio decisions, development strategy, and regulatory planning across the pipeline. The successful candidate will combine strategic leadership with hands-on scientific and operational execution and will help shape how the clinical pharmacology function grows at Rhythm. Responsibilities will include the design, implementation, and interpretation of clinical pharmacology studies to support dose selection, exposure-response characterization, and combination regimen development. This individual will work

### Nuclear Medicine Tech Lead - CommonSpirit Health
- Location: UNAVAILABLE, UNAVAILABLE, UNAVAILABLE (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-16
- 401(k) match: listed (not source-backed)
- Apply: https://careers-commonspirit.icims.com/jobs/508916/nuclear-medicine-tech-lead/job
- Excerpt: Nuclear Medicine Tech Lead UNAVAILABLE, UNAVAILABLE, UNAVAILABLE Where You'll Work St. Anthony Summit Hospital is a Level III trauma center serviced by Flight For Life Colorado. We are nationally recognized as a multiple-time recipient of the Press Ganey Guardian of Excellence Award for Patient Experience, and we were named a Top 100 Hospital in the U.S. by IBM Watson Health in 2018. We also are a Pathway to Excellence-designated hospital, recognized by the American Nurses Credentialing Center as being one of the best hospitals for nurses to work. We provide a full range of medical specialties and health care services to Summit County and the surrounding region, including surgical, emergency/trauma, critical care, birth center, orthopedics, breast care, digital mammography, breast MRI, radiology and imaging, infusion therapy, nuclear medicine, cardiology, oncology, Summit Sleep Disorders Center, Ear Nose and Throat (ENT), gastroenterology and Total Joint Replacement. We proudly provide convenient care where you live, work and play - that's why visitors and residents alike can count on us for emergent and urgent medical services. In addition to 24/7, Level III emergency care at St. Anthony-Summit Hospital in Frisco, we have three emergency mountain clinics at the base of the Breckenridge, Copper Mountain and Keystone resorts, as well as urgent care and primary care available from CMG High Country Healthcare clinics in Frisco, Breckenridge and Silverthorne. Job Summary and Responsibilities As our Nuclear Medicine Tech Lead, you will provide diagnostic and therapeutic nuclear medicine procedures, administer radiopharmaceuticals, operate imaging equipment, and offer shift

### Certified Nursing Assistant (CNA) - Summit Float Pool - Advocate Health
- Location: Aurora Medical Center Summit - 36500 Aurora Dr (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-09
- 401(k) match: listed (not source-backed)
- Apply: https://aah.wd115.myworkdayjobs.com/External/job/Aurora-Medical-Center-Summit---36500-Aurora-Dr/Certified-Nursing-Assistant--CNA----Summit-Float-Pool_R276806
- Excerpt: Certified Nursing Assistant (CNA) - Summit Float Pool Aurora Medical Center Summit - 36500 Aurora Dr Department: 34102 AMC Summit - Nursing Float Pool Status: Part time Benefits Eligible: Yes Hou rs Per Week: 24 Schedule Details/Additional Information: 6:30PM to 7AM, 2-12 hour shifts/week, alternating weekends and holidays Pay Range: $20.80 - $31.20 Major Responsibilities: Assists RN with daily care of patients including bathing, oral hygiene, feeding, activity orders and ambulation which may include use of therapeutic assistive devices, proper positioning, range of motion and special transferring as indicated. Measures and documents blood pressures, TPRs (Temperature, Pulse, Respiration), I & O (Intake and Output), daily weights, and other patient data as requested. Documents accurately in Electronic Medical Record (EMR). Performs purposeful rounding under direction of RN and promptly communicates observations, concerns, and needs of patient/family to RN. Documents appropriately. Participates in admission, transfer and discharge process under supervision of RN including room set up, orientation to room, removing linen, and proper management of patient belongings. Ensures patient call light is always in reach of patient and answers call-lights promptly. Collects urine, stool, and sputum specimens and performs point-of-care testing as indicated using approved process for accurate specimen labeling and identification. Maintains competency as required. Completes various errands as directed including pick-up and delivery of trays, charts, specimens, and reports. Maintains and orders stock for nursing area. Cleans equipment and work areas. Performs various patient positioning and transporting duties which require lifting and pushing/pulling while utilizing proper technique and assistive devices.

### Senior Clinical Trial Associate - Definium Therapeutics
- Location: Remote (remote)
- Salary: $100K-$140K
- Posted: 2026-11-16
- 401(k) match: listed (not source-backed)
- Apply: https://job-boards.greenhouse.io/definiumtherapeutics/jobs/6262558004
- Excerpt: Senior Clinical Trial Associate Remote Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. Together we are moving psychiatry forward-beyond better, into a boundless future. Join us! POSITION SUMMARY: The Senior Clinical Trial Associate, Clinical Operations, plays a key role in administratively supporting the planning, execution, and management of clinical trials within the organization. The Senior CTA works closely with the clinical operations team to ensure the successful implementation of clinical trials, adherence to regulatory guidelines, and the collection of high-quality data. The Senior Clinical Trial Associate is a senior administrative role

### Region Business Director - Mid Atlantic - Corcept Therapeutics
- Location: United States (unspecified)
- Salary: $239K-$281K
- Posted: 2026-10-29
- 401(k) match: listed (not source-backed)
- Apply: https://www.corcept.com/careers/current-opportunities/?gh_jid=6230340004
- Excerpt: Region Business Director - Mid Atlantic United States For more than 25 years, Corcept has been singularly focused on the science of cortisol, a powerful hormone that when unregulated, can play a role in a broad range of diseases. Our commercial portfolio includes treatments for hypercortisolism and oncology, and the company has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. With advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease, Corcept is unlocking the power of cortisol modulation to help address some of the most devastating diseases patients face today. Corcept is headquartered in Redwood City, California. To learn more, visit www.corcept.com . The Region Business Director will lead the strategic launch for Corcept's entry to the oncology commercial market. This position requires a dynamic sales leader with a demonstrated ability to lead and inspire a sales team that is aligned to a high performance and patient centric culture. This leader understands the complexities of the oncology market and aligns strategic plans that maximize both individual and team accountabilities. A strong leader with a proven track record of launching teams and products into the Oncology market is a requirement. Responsibilities: - Cultivate a 'high trust' culture that inspires excellence, puts people first, and that works together to bring out the best in individuals with an unwavering commitment to patients - Collaborate with cross-functional leaders and teams to develop comprehensive brand and sales strategies. Lead the execution of these strategies to drive revenue

### CNA (Certified Nursing Assistant) - Summit Float Pool - Advocate Health
- Location: Aurora Medical Center Summit - 36500 Aurora Dr (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-16
- 401(k) match: listed (not source-backed)
- Apply: https://aah.wd115.myworkdayjobs.com/External/job/Aurora-Medical-Center-Summit---36500-Aurora-Dr/CNA--Certified-Nursing-Assistant----Summit-Float-Pool_R275000-1
- Excerpt: CNA (Certified Nursing Assistant) - Summit Float Pool Aurora Medical Center Summit - 36500 Aurora Dr Department: 34102 AMC Summit - Nursing Float Pool Status: Full time Benefits Eligible: Yes Hou rs Per Week: 36 Schedule Details/Additional Information: 3- 12 hour shifts/week (1830-0700), every third weekend and alternating holidays based on department rotation Pay Range: $20.80 - $31.20 Major Responsibilities: Assists RN with daily care of patients including bathing, oral hygiene, feeding, activity orders and ambulation which may include use of therapeutic assistive devices, proper positioning, range of motion and special transferring as indicated. Measures and documents blood pressures, TPRs (Temperature, Pulse, Respiration), I & O (Intake and Output), daily weights, and other patient data as requested. Documents accurately in Electronic Medical Record (EMR). Performs purposeful rounding under direction of RN and promptly communicates observations, concerns, and needs of patient/family to RN. Documents appropriately. Participates in admission, transfer and discharge process under supervision of RN including room set up, orientation to room, removing linen, and proper management of patient belongings. Ensures patient call light is always in reach of patient and answers call-lights promptly. Collects urine, stool, and sputum specimens and performs point-of-care testing as indicated using approved process for accurate specimen labeling and identification. Maintains competency as required. Completes various errands as directed including pick-up and delivery of trays, charts, specimens, and reports. Maintains and orders stock for nursing area. Cleans equipment and work areas. Performs various patient positioning and transporting duties which require lifting and pushing/pulling while utilizing

### Registered Nurse (RN) New Graduate - Medical/Surgical - Advocate Health
- Location: Aurora Medical Center Summit - 36500 Aurora Dr (unspecified)
- Salary: Not disclosed
- Posted: 2026-10-19
- 401(k) match: listed (not source-backed)
- Apply: https://aah.wd115.myworkdayjobs.com/External/job/Aurora-Medical-Center-Summit---36500-Aurora-Dr/Registered-Nurse--RN----Medical-Surgical_R274175
- Excerpt: Registered Nurse (RN) New Graduate - Medical/Surgical Aurora Medical Center Summit - 36500 Aurora Dr Department: 35814 AMC Summit - Med Surg: IU 4th Floor Status: Full time Benefits Eligible: Yes Hou rs Per Week: 36 Schedule Details/Additional Information: 0.9 FTE Night Shift 1900-0730, weekend and holiday rotation per unit requirements. Pay Range: $38.20 - $57.30 Registered Nurse (RN) - Med/Surg 4 East Unit Summit, WI, United States Where You Will Work: 4 East Medical Surgical is an 18 bed unit that cares for a vast variety of medical and post-operative patient with an emphasis on observation status. Observation patients generally stay on the unit 24-48 hours. Common diagnoses included but are not limited to: chest pain, abdominal pain, back pain, migraine/headache, allergic conditions, asthma, COPD, DVT/VTE, syncope, skin and soft tissue infection, dehydration, electrolyte abnormalities, hypo/hyperglycemia, routine post-op patients, and renal colic. We're Looking For: Completion of an accredited or approved program in nursing Registered Nurse license issued by the state in which the teammate practices Basic Life Support (BLS) for Healthcare Providers certification issued by the American Heart Association What You'll Do: As a skilled and compassionate RN, you will play a pivotal role in providing and coordinating comprehensive patient care through the nursing process to deliver safe, therapeutic care in accordance with established standards, policies, and procedures. Using evidence-based practice, clinical decision making, compassion, and skills communication while leading efforts to create the safest patient environment and the best patient experience across the continuum. About This Location:

### Senior Director, Regulatory Strategy Program Lead - Rapport Therapeutics Inc
- Location: 99 High Street, Suite 2100 , Boston, MA 02110 (unspecified)
- Salary: $275K-$300K
- Posted: 2026-11-05
- Apply: https://www.rapportrx.com/careers-board/?gh_jid=5284491007
- Excerpt: Senior Director, Regulatory Strategy Program Lead 99 High Street, Suite 2100 , Boston, MA 02110 When our people share why they joined Rapport and love it here, it comes down to three things: the science, the mission, and the team. At Rapport, we're driven by a passion for developing precision neuromedicines with the potential for fewer side effects, enabling patients and their families to enjoy healthier, more fulfilling lives. And we're doing this with extraordinary science and awesome people (affectionately called Rapptors). Our innovative scientific platform is centered on Receptor Associate Proteins (RAPs). RAPs are a component of neuronal receptor complexes, which play a crucial role in regulating receptor assembly and function. This precision approach has the potential to revolutionize the development of small molecule therapies. We are excited about the potential of our lead program, RAP-219. Our first indication targets focal epilepsy with additional clinical trials in primary generalized tonic-clonic seizures (PGTCS) and bipolar disorder. The strength of Rapport comes from our Rapptors - who are united by our mission to improve patients lives. We bring the heart and hustle to advance our science forward, always staying true to our core values. We hope you're as excited about this opportunity as we are! The ideal candidate for this role is based in Boston, MA with onsite presence Monday-Wednesday; this role is also open to remote candidates. Your impact: As the regulatory lead for RAP-219 and Bipolar Mania trials, you'll help shape the path from promising science to a potential

### Physical Therapist II, Acute Care, Short Hour - Sutter Health
- Location: Oakland, California, United States of America (unspecified)
- Salary: 63.78-89.28/hr
- Posted: 2026-11-06
- 401(k) match: listed (not source-backed)
- Apply: https://wd1.myworkdaysite.com/recruiting/sutterhealth/SH/job/Oakland/Physical-Therapist-II--Acute-Care--Short-Hour_R-137863/apply
- Excerpt: Physical Therapist II, Acute Care, Short Hour Oakland, California, United States of America We are so glad you are interested in joining Sutter Health! Organization: ABSMC-Alta Bates Summit Med Center Position Overview: At Alta Bates Summit Medical Center, our Physical Therapists play a vital role in helping patients regain function, restore mobility, reduce pain, and achieve their highest level of independence following illness, injury, or surgery. This position is responsible for evaluating patient needs, developing individualized treatment plans, and implementing evidence-based therapeutic interventions across a diverse patient population. The Physical Therapist partners closely with patients, families, caregivers, and interdisciplinary healthcare teams to deliver exceptional, patient-centered care. Through clinical expertise, compassionate communication, and ongoing assessment, the Physical Therapist fosters trust and engagement while supporting positive outcomes throughout the rehabilitation journey. This role also provides clinical leadership through the supervision of physical therapist assistants and rehabilitation aides, serves as a clinical instructor for students, and contributes to a culture of excellence, collaboration, and continuous learning. Adherence to all regulatory, accreditation, and organizational standards is essential to ensuring patient safety, privacy, and quality of care. Why Alta Bates Summit Medical Center? Join a nationally recognized healthcare organization committed to innovation, collaboration, and delivering outstanding rehabilitation services. You'll work alongside dedicated clinicians in a dynamic environment that values professional growth, clinical excellence, and compassionate care for the communities we serve. Job Description : These Principal Accountabilities, Requirements and Qualifications are not exhaustive, but are merely the most descriptive of the current job. Management reserves

### Head of Marketing & Sales - Tango Therapeutics Inc
- Location: Boston, MA (unspecified)
- Salary: $302K-$452K
- Posted: 2026-09-06
- 401(k) match: listed (not source-backed)
- Apply: https://job-boards.greenhouse.io/tangotherapeutics/jobs/7986730003
- Excerpt: Head of Marketing & Sales Boston, MA Company Overview Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts. Summary As Tango transitions into a fully integrated, commercial-stage biopharmaceutical organization, the Vice President of Marketing and Sales will serve as a core pillar of the Commercial Leadership Team. Reporting to the Chief Commercialization Officer, this executive will be responsible for architecting the overarching commercial strategy, establishing our market presence, and driving the successful launch of our precision oncology assets, starting with our oral PRMT5 inhibitors. The ideal candidate brings an enterprise mindset and a proven track record of successfully launching oral oncology therapies. By combining the rigorous, scaled commercial discipline of large, established pharmaceutical organizations with the agility and entrepreneurial spirit of a fast-paced biotech, this leader will build a high-impact, scientifically driven commercial organization. Success in this role requires exceptional cross-functional leadership, guiding overarching corporate strategy, and ensuring seamless integration across commercial, scientific, and

### GI (Endoscopy) and Pain Management Tech - Advocate Health
- Location: Aurora Medical Center Summit - 36500 Aurora Dr (unspecified)
- Salary: Not disclosed
- Posted: 2026-10-28
- 401(k) match: listed (not source-backed)
- Apply: https://aah.wd115.myworkdayjobs.com/External/job/Aurora-Medical-Center-Summit---36500-Aurora-Dr/GI--Endoscopy--and-Pain-Management-Tech_R273782
- Excerpt: GI (Endoscopy) and Pain Management Tech Aurora Medical Center Summit - 36500 Aurora Dr Department: 36802 AMC Summit - Gastrointestinal Services Status: Full time Benefits Eligible: Yes Hou rs Per Week: 36 Schedule Details/Additional Information: 36 hours/wk position working in GI and Pain. Position will involve approximately 70% GI procedures (upper/lower endo and colonoscopies, scope cleaning) and 30% pain procedures (local injections, RFA procedures, neuro stimulator implants). 8-hour shifts, Monday-Friday, rotation of 5 days/ 4 days, typically 0700-1530 but can vary at times based on schedule. Will require nightly call (once per week), weekend call (every 4th weekend (Fri-Mon) and holiday call (2 holidays per year). *Call requirement means that you must be able to receive the phone call and be onsite in 40 minutes. Pay Range: $20.80 - $32.80 Pain Management Technician Major Responsibilities: Performs and/or assists in surgical, diagnostic and therapeutic procedures including epidural steroid injections, neuro stimulator electrode implants, trigger point injections, lumbar sympathetic blocks, regional IV administrations, epidural catheter insertions, radio frequency ablations (RFA's), nerve injections with neurolysis, discographies, vertebralplasties and kyphoplasties. Performs point of care testing and records results. Monitors patient's vital signs before, during, and after procedures. Organizes and prepares procedure room ensuring proper sterilization of instruments and equipment. Provides basic instructions and answers patient's questions prior to procedures. Refers complex questions to RN's or physicians. Maintains working knowledge of all procedural equipment in the department and conducts routine maintenance suggested by the manufacturer and outlined in department policies and procedures. Processes patient prescription

### Executive Director, Clinical Development - Mineralys Therapeutics Inc
- Location: US Remote (remote)
- Salary: $340K-$370K
- Posted: 2026-04-21
- Apply: https://job-boards.greenhouse.io/mineralystherapeutics/jobs/5195429008
- Excerpt: Executive Director, Clinical Development US Remote “Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is headquartered in Radnor, Pennsylvania. For more information, please visit https://mineralystx.com . Follow Mineralys on LinkedIn , Twitter and Bluesky ” Mineralys is a fully remote company. Executive Director, Clinical Development The Executive Director, Clinical Development will serve as the clinical lead for development program(s) and play a critical role in advancing pivotal studies, regulatory strategy, and submission readiness. This physician leader will provide medical and scientific oversight across the program lifecycle, from protocol design and study execution through data interpretation, regulatory interactions, and launch preparation. This role requires a hands-on clinical development leader who thrives in a fast-paced biotech environment and can partner cross-functionally to drive high-quality execution with urgency. Key Responsibilities: Clinical Development Leadership - Serve as the clinical lead for one or more clinical programs, with responsibility for clinical trial design, execution oversight, and delivery of key milestones. - Lead development of clinical plans, protocols, amendments, , and related study documents. - Provide medical oversight for Phase 2/3 and/or registrational studies, ensuring patient safety, data integrity, and operational excellence. - Partner with Clinical Operations, Biostatistics, Data Management, Regulatory, and Safety to ensure efficient study execution and timely issue resolution. - Drive

### Senior Director, Clinical Trial Liaison Strategy - Regeneron Pharmaceuticals
- Location: 3 Locations (unspecified)
- Salary: $216K-$360K
- Posted: 2026-10-19
- Parental leave: 12 weeks (not source-backed)
- Non-birth-parent leave: 12 weeks (not source-backed)
- 401(k) match: listed (not source-backed)
- Apply: https://regeneron.wd1.myworkdayjobs.com/Careers/job/TARRYTOWN/Senior-Director--Clinical-Trial-Liaison-Strategy_R50397
- Excerpt: Senior Director, Clinical Trial Liaison Strategy 3 Locations Build our future together: At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Head of Clinical Trial Liaison to join our Global Site Management team within Global Clinical Operations. As a senior leader within Global Clinical Operations, you will work with abstract ideas and objectives to solve complex, often precedent-setting problems, directing strategy implementation for a broad, business-critical function spanning multiple disciplines, regions, and study teams. You will lead the activities of a diverse, global team, building and sustaining an industry-leading, field-based operational capability enabled by people, process, and technology, and own line management of Director, CTL Regional Heads. You will partner closely with cross-functional stakeholders and senior leaders across Global Development to align and execute a portfolio-wide, multi-year operational strategy for field-based clinical trial support, reporting into the Head of Global Site Management. This position offers the opportunity to contribute to a fast-growing, science-driven organization making a meaningful difference to patients worldwide. When & where: Location: Preferred: Tarrytown, NY, Warren, NJ, Cambridge, MA, or Remote Work model/flexibility: Primarily on-site with hybrid flexibility Travel percentage: 30-40% Discover your role: Direct strategy implementation for a business-critical, multi-disciplinary field-based operations capability spanning multiple regions Lead the activities of a diverse, global team; own individual career development, performance management, and succession planning for the CTL organization Establish broad, function-wide objectives and develop, modify, and oversee organization-wide policies and processes Provide strategic business oversight of

### Occupational Therapy Assistant II, Per Diem - Sutter Health
- Location: Oakland, California, United States of America (unspecified)
- Salary: 45.18-63.25/hr
- Posted: 2026-08-10
- 401(k) match: listed (not source-backed)
- Apply: https://wd1.myworkdaysite.com/recruiting/sutterhealth/SH/job/Oakland/Occupational-Therapy-Assistant-II--Per-Diem_R-137697/apply
- Excerpt: Occupational Therapy Assistant II, Per Diem Oakland, California, United States of America We are so glad you are interested in joining Sutter Health! Organization: ABSMC-Summit Campus Position Overview: Join a patient-centered rehabilitation team committed to helping individuals achieve greater independence, function, and quality of life. As an Occupational Therapy Assistant (OTA), you will work under the supervision of a licensed Occupational Therapist to deliver individualized therapeutic interventions that help patients improve their ability to perform meaningful daily activities. In this role, you will provide occupational therapy treatments according to established plans of care, support patients in achieving functional goals, and contribute to positive patient outcomes through compassionate, evidence-based care. You will collaborate closely with occupational therapists, physicians, nurses, and other healthcare professionals to ensure a coordinated approach to treatment. The Occupational Therapy Assistant may assist with treatment planning, perform therapeutic activities and interventions, document patient progress, and modify treatments within the scope of the established plan of care and state practice guidelines. Success in this role requires strong clinical skills, excellent communication, and a passion for helping patients regain and maintain independence. What You'll Do: Implement individualized occupational therapy treatment plans under the direction of a licensed Occupational Therapist. Provide therapeutic interventions that support patients in improving functional abilities, self-care skills, mobility, and participation in daily activities. Monitor patient progress and communicate treatment outcomes with the interdisciplinary care team. Educate patients and caregivers on therapeutic strategies, adaptive equipment, and techniques to promote independence and safety. Maintain accurate and timely clinical

### Head of Insights & Analytics - Tango Therapeutics Inc
- Location: Boston, MA (unspecified)
- Salary: $275K-$413K
- Posted: 2026-09-06
- 401(k) match: listed (not source-backed)
- Apply: https://job-boards.greenhouse.io/tangotherapeutics/jobs/7986609003
- Excerpt: Head of Insights & Analytics Boston, MA Company Overview Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts. Summary The Executive Director, Insights and Analytics (ED I&A) is a strategic enterprise leader responsible for building, scaling, and leading Tango Therapeutics' Insights and Analytics center of excellence. As Tango transitions from a research-stage biotech into a fully integrated commercial organization, this executive will define the enterprise-wide data, analytics, and insights strategy to support the successful launch and lifecycle management of our precision synthetic lethality oral medicines. Reporting directly to the Chief Commercialization Officer (CCO), the ED of I&A will serve as a critical member of the Commercial Leadership Team and cross-functional strategy teams. This leader will act as an indispensable thought partner to executive leadership, translating complex data ecosystems into actionable insights that influence enterprise direction, optimize performance, and drive data-driven decision-making across Sales, Marketing, Market Access, Medical Affairs, and Finance. The ED of I&A

### Senior Developer (Summit & C++) - Assistant Vice President - State Street Corporation
- Location: 3 Locations (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-05
- 401(k) match: listed (not source-backed)
- Apply: https://statestreet.wd1.myworkdayjobs.com/Global/job/Bangalore-India/Senior-Developer--Summit---C------Assistant-Vice-President_R-795700
- Excerpt: Senior Developer (Summit & C++) - Assistant Vice President 3 Locations Job Description: State Street is looking for a Developer with 15 - 18 years' experience in C++ and Summit API development. The candidate must have experience in Financial Services and Summit. Role Description & Responsibilities: Overall 15 - 18 plus experience. Proficiency in investment banking and capital markets domain. Understanding of OTC(over-the counter)derivatives products and fixed income products. Experience in understanding and implementing client requirements independently and effectively. Core/Must have skills: Design ,develop and maintain solution in C++ programming language. Knowledge of various Summit APIs and Components Customize and develop Reports, Blotter extension and STP using Summit APIs . Proficient in Unix, Shell scripting . Clearly can explain the underlying Summit architecture and related technical areas Database experience preferably Oracle Proficient in Git, Jira Good to have skills: Skill 1 - Cloud exposure/experience Skill 2 - Python programming language Skill 3- Basic understanding on OTC products and Fixed income products Note: We're looking for candidates who can bring a powerful combination of hands-on SUMMIT and C++ expertise to the role. If you're equally experienced working across both technologies, we'd be excited to hear from you. For SUMMIT in particular, we're seeking deep technical expertise-someone who can confidently navigate its complexities, troubleshoot challenging scenarios, and work comfortably with its more advanced aspects. To ensure the right fit, please apply only if you have strong, practical experience in both SUMMIT and C++. If your experience doesn't currently align with both areas,

### Visual Associate, Part Time Flex, Summit - West Elm - Williams-Sonoma, Inc.
- Location: Summit, NJ, United States (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-02
- 401(k) match: listed (not source-backed)
- Apply: https://ehac.fa.us6.oraclecloud.com/hcmUI/CandidateExperience/en/sites/CX_1/requisitions/job/20884
- Excerpt: Visual Associate, Part Time Flex, Summit - West Elm Summit, NJ, United States Visual Merchandiser supports management team in achieving goals by providing World-Class service. Serves as a role model for building relationships with customers. Maintains presence through store supervision to ensure appropriate staff coverage areas.

### Director, Clinical Business Operations - Rapport Therapeutics Inc
- Location: 99 High Street, Suite 2100 , Boston, MA 02110 (unspecified)
- Salary: $230K-$255K
- Posted: 2026-06-26
- Apply: https://www.rapportrx.com/careers-board/?gh_jid=5174775007
- Excerpt: Director, Clinical Business Operations 99 High Street, Suite 2100 , Boston, MA 02110 When our people share why they joined Rapport and love it here, it comes down to three things: the science, the mission, and the team. At Rapport, we're driven by a passion for developing precision neuromedicines with the potential for fewer side effects, enabling patients and their families to enjoy healthier, more fulfilling lives. And we're doing this with extraordinary science and awesome people (affectionately called Rapptors). Our innovative scientific platform is centered on Receptor Associate Proteins (RAPs). RAPs are a component of neuronal receptor complexes, which play a crucial role in regulating receptor assembly and function. This precision approach has the potential to revolutionize the development of small molecule therapies. We are excited about the potential of our lead program, RAP-219. Our first indication targets focal epilepsy with additional clinical trials in primary generalized tonic-clonic seizures (PGTCS) and bipolar disorder. The strength of Rapport comes from our Rapptors - who are united by our mission to improve patients lives. We bring the heart and hustle to advance our science forward, always staying true to our core values. We hope you're as excited about this opportunity as we are! This role is based in Boston, MA with onsite presence required Monday-Wednesday Your impact: Behind every successful clinical trial is a strong business foundation. In this role, you'll build and lead that foundation by overseeing budgets, financial planning, vendor partnerships, contracts, and portfolio operations that enable our clinical

### Senior Director, DMPK - Cogent Biosciences Inc
- Location: Boulder, Colorado, United States (unspecified)
- Salary: $255K-$290K
- Posted: 2026-11-17
- 401(k) match: listed (not source-backed)
- Learning budget: yes (not source-backed)
- Apply: https://job-boards.greenhouse.io/cogentbiosciences/jobs/4511063009
- Excerpt: Senior Director, DMPK Boulder, Colorado, United States Who We Are: Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has exhibited promising initial data across all three trials: APEX in AdvSM, SUMMIT in NonAdvSM and PEAK in GIST, including an encouraging safety profile across 600+ patients in single agent and combination dosing. The Role: The Senior Director, DMPK is responsible for providing scientific and strategic leadership for Drug Metabolism and Pharmacokinetics activities across Cogent's discovery and development portfolio. This individual will lead the DMPK function and develop and execute DMPK strategies that support small molecule programs from early discovery through candidate selection, IND-enabling studies, and clinical development. The successful candidate will bring deep expertise in ADME, pharmacokinetics, bioanalysis, and translational DMPK and will work closely with Medicinal Chemistry, Biology, Pharmacology, Toxicology, Clinical Pharmacology, and other cross-functional partners. This role will lead an internal DMPK team and oversee external CROs and partners to ensure high-quality data and timely execution of program objectives. The ideal candidate is a highly collaborative scientific leader

### Design Sales Specialist/Home Stylist, Part Time Flex, Summit - West Elm - Williams-Sonoma, Inc.
- Location: Summit, NJ, United States (unspecified)
- Salary: Not disclosed
- Posted: 2026-09-19
- 401(k) match: listed (not source-backed)
- Apply: https://ehac.fa.us6.oraclecloud.com/hcmUI/CandidateExperience/en/sites/CX_1/requisitions/job/20443
- Excerpt: Design Sales Specialist/Home Stylist, Part Time Flex, Summit - West Elm Summit, NJ, United States Our mission is to enhance the quality of our customers' lives at home. We put the customer at the center of everything we do, every day. Our corporate values that guide our actions and decisions are our People First culture, customers, quality, shareholders, integrity, and corporate responsibility.

### Lead Sales (Key Holder), Full Time, Summit - West Elm - Williams-Sonoma, Inc.
- Location: Summit, NJ, United States (unspecified)
- Salary: Not disclosed
- Posted: 2026-08-28
- 401(k) match: listed (not source-backed)
- Apply: https://ehac.fa.us6.oraclecloud.com/hcmUI/CandidateExperience/en/sites/CX_1/requisitions/job/20010
- Excerpt: Lead Sales (Key Holder), Full Time, Summit - West Elm Summit, NJ, United States Our mission is to enhance the quality of our customers' lives at home. We put the customer at the center of everything we do, every day. Our corporate values that guide our actions and decisions are our People First culture, customers, quality, shareholders, integrity, and corporate responsibility.

### Medical Director - Perspective Therapeutics Inc
- Location: Location not specified (unspecified)
- Salary: Not disclosed
- Posted: 2026-06-21
- Apply: https://perspectivetherapeutics.applytojob.com/apply/NjNJ4qax0m/Medical-Director
- Excerpt: Medical Director Objective Reporting to the Chief Medical Officer, the Medical Director will lead clinical development strategy and clinical operations for active programs. Duties will include management of cross-functional, multidisciplinary study teams, and oversight for the design and execution of clinical trials. S/he will serve as the Medical Lead and primary Medical Monitor for clinical trials. The Medical Director will work closely with all matrixes of the team including scientists in discovery research, clinical operations, and regulatory affairs. The Medical Director will also participate in advisory meetings with opinion leaders and academic study investigators and will support interactions with Health Authorities. Essential Functions Lead the development of study protocols, statistical analysis plans, investigators brochures, and other key study documents in conjunction with Perspective Leadership and key advisors. Prepare the clinical development plans with support from cross functional team members. Perform regular data reviews (including e.g. PK, safety, efficacy). Provide leadership on cross-functional study teams for assigned trials, working with other team members to achieve efficient, high-quality study execution and data analysis. Participate in the preparation of regulatory documents in support of regulatory submissions, including clinical section of INDs and CTAs, safety reports, responses to regulatory authorities, clinical study reports, and other documents as appropriate, and interface with regulatory authorities as needed. Communicate with and inspire key external stakeholders to facilitate the development and medical oversight of Perspective compounds. Stakeholders and mechanisms of outreach may include: Investigators, Medical Community (e.g., KOLs) Preparation and presentation of abstracts/oral presentations at conferences, and writing

### Lees Summit, MO Loan Originator - Hilltop Holdings Inc
- Location: Lees Summit, MO, United States (unspecified)
- Salary: Not disclosed
- Posted: 2025-05-19
- 401(k) match: listed (not source-backed)
- Apply: https://ejlu.fa.us2.oraclecloud.com:443/hcmUI/CandidateExperience/en/sites/HilltopHoldingsAllJobs/requisitions/job/31268
- Excerpt: Lees Summit, MO Loan Originator Lees Summit, MO, United States Under the direction of the Branch and/or Production Manager, markets and promotes PrimeLending products and services to its client base of realtors, builders, bank officers and potential and past clients. Performs office or non-manual work directly related to the management or general business operations of PrimeLending and its customers.

### Director, Clinical Contracts - Rapport Therapeutics Inc
- Location: 99 High Street, Suite 2100 , Boston, MA 02110 (unspecified)
- Salary: $195K-$215K
- Posted: 2026-09-22
- Apply: https://www.rapportrx.com/careers-board/?gh_jid=5244494007
- Excerpt: Director, Clinical Contracts 99 High Street, Suite 2100 , Boston, MA 02110 When our people share why they joined Rapport and love it here, it comes down to three things: the science, the mission, and the team. At Rapport, we're driven by a passion for developing precision neuromedicines with the potential for fewer side effects, enabling patients and their families to enjoy healthier, more fulfilling lives. And we're doing this with extraordinary science and awesome people (affectionately called Rapptors). Our innovative scientific platform is centered on Receptor Associate Proteins (RAPs). RAPs are a component of neuronal receptor complexes, which play a crucial role in regulating receptor assembly and function. This precision approach has the potential to revolutionize the development of small molecule therapies. We are excited about the potential of our lead program, RAP-219. Our first indication targets focal epilepsy with additional clinical trials in primary generalized tonic-clonic seizures (PGTCS) and bipolar disorder. The strength of Rapport comes from our Rapptors - who are united by our mission to improve patients lives. We bring the heart and hustle to advance our science forward, always staying true to our core values. We hope you're as excited about this opportunity as we are! This role is based in Boston, MA with onsite presence required Monday-Wednesday Your impact: As our Director of Clinical Contracts, you'll help turn clinical plans into action. You'll own clinical trial agreements, site budgets, and vendor contracts while partnering with Clinical Ops, Legal, Finance, and our CROs to keep

### Senior Product Leader, Therapeutics Discovery - Genentech, Inc.
- Location: South San Francisco, California, United States of America (unspecified)
- Salary: $126K-$234K
- Posted: 2026-11-02
- 401(k) match: listed (not source-backed)
- Relocation assistance: yes (not source-backed)
- Apply: https://roche.wd3.myworkdayjobs.com/ROG-A2O-GENE/job/South-San-Francisco/Senior-Product-Leader--Therapeutics-Discovery_202611-128152/apply
- Excerpt: Senior Product Leader, Therapeutics Discovery South San Francisco, California, United States of America A healthier future. It's what drives us to innovate. To continuously advance science and ensure everyone has access to the healthcare they need today and for generations to come. Creating a world where we all have more time with the people we love. That's what makes us Roche. The Computational Sciences Center of Excellence (CS CoE) brings together scientific, data and computational capabilities to support research and early development across Genentech (gRED) and Pharma (pRED). Within CS CoE, Data and Digital Catalysts (DDC) bridges the informatics and scientific communities to create solutions that power scientific discovery and accelerate decision-making. Reporting to the Therapeutics Discovery Domain Head, you will own a defined subset of scientific informatics products that enable assay request, setup, execution and experimental data capture. Your focus will be to make data and metadata capture an integral part of experimental work: establishing the required scientific context before data are generated, capturing it as early as possible, and preserving what actually happened during execution. These products should support the original scientific purpose while making results interpretable, traceable and reusable for scientific analysis, decision-making and machine learning. The remit spans therapeutic modalities, with an emphasis on adaptable workflows that can support all drug discovery modalities over time. The Opportunuity: As an integral member of this dynamic team, you will be: Product ownership and prioritization. Own the roadmap, prioritization and outcomes for assigned products within a product family. Contribute

### PRN Recreational Therapist - Summit BHC
- Location: Carolina Dunes Behavioral Health (unspecified)
- Salary: Not disclosed
- Posted: 2026-10-20
- Apply: https://summitbhc.wd1.myworkdayjobs.com/Summit_BHC/job/Carolina-Dunes-Behavioral-Health/PRN-Recreational-Therapist_JR127251
- Excerpt: PRN Recreational Therapist Carolina Dunes Behavioral Health PRN Recreational Therapist | Carolina Dunes Behavioral Health | Leland, North Carolina About the Job: PURPOSE STATEMENT: The Activity Therapist plans, organizes, and conducts comprehensive recreational therapy services as a component of the patient's treatment plan designed to assist the patient with learning healthy coping skills, strengths, hobbies, and assist with the development of social skills/relationships. Ensures all programming is consistent with accepted standards of practice and established policies and procedures. Roles and Responsibilities: ESSENTIAL FUNCTIONS: Performs patient assessments through patient/family interview, obtaining information on the patient's needs, skills, interests, strengths, and limitations for the development and implementation of individualized treatment plan. Plans and implements an activities program including but not limited to therapeutic leisure skills and activities, leisure education and leisure awareness to provide quality activities programs that meet patient needs and interests and helps the patient achieve his/her treatment goals. Coordinates patient activities while providing a safe environment. Orients patients to the activities program, explaining the benefits of the activities to the patients. Engages patients in therapeutic activities such as exercise, games sports, dance, music, art or relaxation techniques designed to meet their specific needs. Monitors and evaluates patient's progress, interest levels, attitude, and behaviors. Engages patients in individual and/or group recreation programming. Individual and group programming will fall under the five activity domains: physical, social, intellectual, creative and spiritual. Modifies activities to suit the needs of specific groups. Provides patients with activity resources, supplies and equipment, as needed. Requests needed

### Principal Product Leader, Therapeutics Discovery - Genentech, Inc.
- Location: South San Francisco, California, United States of America (unspecified)
- Salary: $149K-$276K
- Posted: 2026-06-11
- 401(k) match: listed (not source-backed)
- Apply: https://roche.wd3.myworkdayjobs.com/ROG-A2O-GENE/job/South-San-Francisco/Principal-Product-Leader--Therapeutics-Discovery_202606-114878-1/apply
- Excerpt: Principal Product Leader, Therapeutics Discovery South San Francisco, California, United States of America A healthier future. It's what drives us to innovate. To continuously advance science and ensure everyone has access to the healthcare they need today and for generations to come. Creating a world where we all have more time with the people we love. That's what makes us Roche. Advances in AI, data, and computational sciences are transforming drug discovery and development. Roche's Research and Early Development organisations at Genentech (gRED) and Pharma (pRED) have demonstrated how these technologies accelerate R&D, leveraging data and novel computational models to drive impact. Seamless data sharing and access to models across gRED and pRED are essential to maximising these opportunities. The new Computational Sciences Center of Excellence (CS CoE) is a strategic, unified group whose goal is to harness this transformative power of data and Artificial Intelligence (AI) to assist our scientists in both pRED and gRED to deliver more innovative and transformative medicines for patients worldwide. The Data and Digital Catalysts (DDC) department within the CS CoE is a diverse, curious and action-driven team at the intersection of science, engineering and computation with ambition to advance our technical excellence. The focus of the team is on bridging the informatics and scientific communities to create a computational and data ecosystem that powers scientific discovery and accelerates decision making. We aim to modernize our ability to acquire, store, link, share, find and analyze data across the organization through scalable and integrated solutions

### Activity Therapist - Acute - Summit BHC
- Location: Peak Behavioral Health (unspecified)
- Salary: Not disclosed
- Posted: 2026-10-19
- Apply: https://summitbhc.wd1.myworkdayjobs.com/Summit_BHC/job/Peak-Behavioral-Health/Activity-Therapist---Acute_JR127260
- Excerpt: Activity Therapist - Acute Peak Behavioral Health Activity Therapist - Acute | Peak Behavioral Health | Santa Teresa, New Mexico About the Job: PURPOSE STATEMENT: The Activity Therapist plans, organizes, and conducts comprehensive recreational therapy services as a component of the patient's treatment plan designed to assist the patient with learning healthy coping skills, strengths, hobbies, and assist with the development of social skills/relationships. Ensures all programming is consistent with accepted standards of practice and established policies and procedures. Roles and Responsibilities: ESSENTIAL FUNCTIONS: Performs patient assessments through patient/family interview, obtaining information on the patient's needs, skills, interests, strengths, and limitations for the development and implementation of individualized treatment plan. Plans and implements an activities program including but not limited to therapeutic leisure skills and activities, leisure education and leisure awareness to provide quality activities programs that meet patient needs and interests and helps the patient achieve his/her treatment goals. Coordinates patient activities while providing a safe environment. Orients patients to the activities program, explaining the benefits of the activities to the patients. Engages patients in therapeutic activities such as exercise, games sports, dance, music, art or relaxation techniques designed to meet their specific needs. Monitors and evaluates patient's progress, interest levels, attitude, and behaviors. Engages patients in individual and/or group recreation programming. Individual and group programming will fall under the five activity domains: physical, social, intellectual, creative and spiritual. Modifies activities to suit the needs of specific groups. Provides patients with activity resources, supplies and equipment, as needed. Requests

### Associate Director, Pharmacovigilance Operations - Definium Therapeutics
- Location: Remote (remote)
- Salary: $160K-$240K
- Posted: 2026-11-17
- 401(k) match: listed (not source-backed)
- Apply: https://job-boards.greenhouse.io/definiumtherapeutics/jobs/6264044004
- Excerpt: Associate Director, Pharmacovigilance Operations Remote Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. Together we are moving psychiatry forward-beyond better, into a boundless future. Join us! Definium Therapeutics, Inc. is seeking a Associate Director, Pharmacovigilance Operations to play a key role in setting and executing on departmental strategy, as well as managing the day-to-day functioning of the Pharmacovigilance department. The incumbent will be responsible for overseeing departmental activities associated with investigational products. This role provides an outstanding opportunity to work in a matrix environment and collaborate with colleagues from Biometrics, Clinical

### Recreational Therapist- Full Time - Summit BHC
- Location: Raleigh Oaks Behavioral Health (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-03
- Apply: https://summitbhc.wd1.myworkdayjobs.com/Summit_BHC/job/Raleigh-Oaks-Behavioral-Health/Recreational-Therapist--Full-Time_JR127897
- Excerpt: Recreational Therapist- Full Time Raleigh Oaks Behavioral Health Recreational Therapist- Full Time | Raleigh Oaks Behavioral Health | Garner, North Carolina About the Job: PURPOSE STATEMENT: The Activity Therapist plans, organizes, and conducts comprehensive recreational therapy services as a component of the patient's treatment plan designed to assist the patient with learning healthy coping skills, strengths, hobbies, and assist with the development of social skills/relationships. Ensures all programming is consistent with accepted standards of practice and established policies and procedures. Roles and Responsibilities: ESSENTIAL FUNCTIONS: Performs patient assessments through patient/family interview, obtaining information on the patient's needs, skills, interests, strengths, and limitations for the development and implementation of individualized treatment plan. Plans and implements an activities program including but not limited to therapeutic leisure skills and activities, leisure education and leisure awareness to provide quality activities programs that meet patient needs and interests and helps the patient achieve his/her treatment goals. Coordinates patient activities while providing a safe environment. Orients patients to the activities program, explaining the benefits of the activities to the patients. Engages patients in therapeutic activities such as exercise, games sports, dance, music, art or relaxation techniques designed to meet their specific needs. Monitors and evaluates patient's progress, interest levels, attitude, and behaviors. Engages patients in individual and/or group recreation programming. Individual and group programming will fall under the five activity domains: physical, social, intellectual, creative and spiritual. Modifies activities to suit the needs of specific groups. Provides patients with activity resources, supplies and equipment, as needed.

### Senior Director, Clinical Trial Patient Safety Lead - Corcept Therapeutics
- Location: Redwood City, California, United States (unspecified)
- Salary: $238K-$316K
- Posted: 2026-10-08
- 401(k) match: listed (not source-backed)
- Apply: https://www.corcept.com/careers/current-opportunities/?gh_jid=6220939004
- Excerpt: Senior Director, Clinical Trial Patient Safety Lead Redwood City, California, United States For more than 25 years, Corcept has been singularly focused on the science of cortisol, a powerful hormone that when unregulated, can play a role in a broad range of diseases. Our commercial portfolio includes treatments for hypercortisolism and oncology, and the company has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. With advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease, Corcept is unlocking the power of cortisol modulation to help address some of the most devastating diseases patients face today. Corcept is headquartered in Redwood City, California. To learn more, visit www.corcept.com . As Corcept's clinical development portfolio and international presence continue to expand, the Patient Safety & Pharmacovigilance (PSPV) organization is expanding its capabilities to support the company's growing pipeline of innovative medicines. We are seeking a talented and experienced leader to serve as Senior Director, Clinical Trial Patient Safety Lead and provide strategic and operational leadership for clinical trial patient safety across the development portfolio. The function includes two complementary areas: Study Management and Safety Data Review . The Senior Director will establish and scale an integrated operating model spanning study safety operations, CRO oversight, safety-data quality, ICSR quality oversight, data reconciliation, query management, data cleaning, and clinical safety data readiness. As a member of the PSPV Leadership Team, this leader will work closely across PSPV (Medical Safety, Safety Sciences, Postmarketing Safety Operations, Safety Systems, Business

### Director of Outpatient Services - Summit BHC
- Location: St. Joseph Institute for Addiction (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-04
- Apply: https://summitbhc.wd1.myworkdayjobs.com/Summit_BHC/job/St-Joseph-Institute-for-Addiction/Director-of-Outpatient-Services_JR127913
- Excerpt: Director of Outpatient Services St. Joseph Institute for Addiction Director of Outpatient Services | St. Joseph Institute for Addiction | Wexford, Pennsylvania About the Job: PURPOSE STATEMENT: The Director of Outpatient Services is responsible for the management and oversight of the day-to-day operations of the outpatient department, planning, implementation, and evaluation of clinical care systems and for client health outcomes attributable to clinical practice. Provides direct supervision to clinical staff and indirect guidance to other staff regarding clinical programming and treatment expectations to ensure effective & safe therapeutic practices are being provided. Leads all aspects of the outpatient counseling/social work programs including Psychosocial Assessments, conducting groups, facilitating family therapies, and developing, implementing, and reviewing Treatment Plans. Oversees all outpatient clinical programs, monitoring the multidisciplinary treatment team process, monitoring discharge planning, and community resource referral. Roles and Responsibilities: ESSENTIAL FUNCTIONS: Plans. develops and implements evidence-based quality programming including all clinical program schedules, as part of the therapeutic environment. Reviews the progress, quality, and effectiveness of all outpatient clinical programs. Identifies and prioritizes issues of importance, including those priority issues as set by leadership. Collaborates with department leaders and corporate leaders, as needed. Communicates instructions, expectations, and timelines clearly and concisely. Provides support and instruction as needed to direct care staff to ensure they adequately understand the treatment program and service delivery expectations to clients based on the clients' individual treatment plans and clinical needs. Ensures that all outpatient clinical programming, staffing, operations, and documentation is in accordance with regulatory agencies and

### Director, Pharmacovigilance Operations - Maplight Therapeutics Inc
- Location: Remote (remote)
- Salary: $205K-$240K
- Posted: 2026-10-16
- 401(k) match: listed (not source-backed)
- Apply: https://job-boards.greenhouse.io/maplighttherapeutics/jobs/5455328008
- Excerpt: Director, Pharmacovigilance Operations Remote Who We Are: MapLight Therapeutics is a clinical stage biotech company that focuses on drug discovery for central nervous system disorders. We combine cutting-edge technologies including optogenetics, in vivo physiology, and spatial transcriptomics to identify novel drug targets and develop effective therapies to address psychiatric symptoms. What You'll Do: The Director, Pharmacovigilance (PV) Operations will lead the strategy, planning, execution, and maintenance of safety databases and outsourced PV activities through partners and contract research organizations. Reporting to the Vice President, Pharmacovigilance, this person will oversee the collection, evaluation, and reporting of safety data from clinical trials, shaping the company's safety governance framework and supporting strategic decisions related to PV operations across programs. Responsibilities: - Develop strategy for PV operations and support PV Head in the implementation of strategy and vision for PV function - Provide strategic leadership for global pharmacovigilance operations, including case management, vendor oversight, and aggregate reporting. - Manage the implementation of MPLT safety system (safety database and process) for regulatory compliant ICSR case processing - Oversight of PV vendor and contract management (e.g. third party CRO, partners) - Oversight of alliance management related to safety (SDEAs) - Manage flow of information and data between clinical and PV vendor in collaboration with Clinical operation (e.g. PV mailbox) - Oversight of quality and compliance for ICSR case processing and reporting (KPI) - Develop, contribute, review and maintain up to date ICSR case processing SOPs, forms, SMPs etc. - Liaise with safety surveillance and cross-functional teams

### Director of Clinical Services - Summit BHC
- Location: Fair Oaks Recovery Center (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-05
- Apply: https://summitbhc.wd1.myworkdayjobs.com/Summit_BHC/job/Fair-Oaks-Recovery-Center/Director-of-Clinical-Services_JR127942
- Excerpt: Director of Clinical Services Fair Oaks Recovery Center Director of Clinical Services | Fair Oaks Recovery Center | Sacramento, California About the Job: PURPOSE STATEMENT: The Director of Clinical Services is responsible for the management and oversight of the day-to-day operations of the clinical department, planning, implementation, and evaluation of clinical care systems and for client health outcomes attributable to clinical practice. Provides direct supervision to clinical staff and indirect guidance to other staff regarding clinical programming and treatment expectations to ensure effective & safe therapeutic practices are being provided. Leads all aspects of the counseling/social work programs including Psychosocial Assessments, conducting groups, facilitating family therapies, and developing, implementing, and reviewing Treatment Plans. Oversees all clinical programs, monitoring the multidisciplinary treatment team process, monitoring discharge planning, and community resource referral. Salary: 113k-150k/annually Roles and Responsibilities: ESSENTIAL FUNCTIONS: Plans, develops and implements evidence-based quality programming including all clinical unit schedules, as part of the therapeutic environment. Reviews the progress, quality, and effectiveness of all clinical programs. Identifies and prioritizes issues of importance, including those priority issues as set by leadership. Collaborates with department leaders and corporate leaders, as needed. Communicates instructions, expectations, and timelines clearly and concisely. Provides support and instruction as needed to direct care staff to ensure they adequately understand the treatment program and service delivery expectations to clients based on the clients' individual treatment plans and clinical needs. Ensures that all clinical programming, staffing, and documentation is in accordance with regulatory agencies and standards of care. Ensures that

### Senior Therapeutic Area Specialist, Neuroscience - COBENFY - Syracuse NY - Bristol Myers Squibb
- Location: Syracuse - NY - US (unspecified)
- Salary: $139K-$169K
- Posted: 2026-10-19
- 401(k) match: listed (not source-backed)
- Apply: https://bristolmyerssquibb.wd5.myworkdayjobs.com/BMS/job/Syracuse---NY---US/Senior-Therapeutic-Area-Specialist--Neuroscience---COBENFY---Syracuse-NY_R1606321
- Excerpt: Senior Therapeutic Area Specialist, Neuroscience - COBENFY - Syracuse NY Syracuse - NY - US At Bristol Myers Squibb, our employees often ask, “Who are you working for?”-a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits. This is work that transforms the lives of patients, and the careers of those who do it. Position: Senior Therapeutic Area Specialist Therapeutic Area (TA): Psychiatry Location: Syracuse NY; Binghamton NY/ Watertown NY At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. The BMS Mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. In oncology, hematology, immunology and cardiovascular disease - and one of the most diverse and promising pipelines in the industry - each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us, build your professional career within one of the most innovative bio-pharma companies, and make a difference. Position Summary: The TAS is a critical role in our unique customer model to execute the BMS aspiration to be the BioPharma that delivers the most impactful engagement with Health Care Providers (HCPs), driving adoption of new and existing medicines for appropriate patients. The

### Director Outpatient Services - Summit BHC
- Location: Cottonwood Tucson (unspecified)
- Salary: Not disclosed
- Posted: 2026-10-30
- Apply: https://summitbhc.wd1.myworkdayjobs.com/Summit_BHC/job/Cottonwood-Tucson/Director-Outpatient-Services_JR127330
- Excerpt: Director Outpatient Services Cottonwood Tucson Director Outpatient Services | Cottonwood Tucson | Tucson, Arizona About the Job: Independent clinical licensure required- LCSW, LPC, etc The Director of Outpatient Services is responsible for the management and oversight of the day-to-day operations of the outpatient department, planning, implementation, and evaluation of clinical care systems and for client health outcomes attributable to clinical practice. Provides direct supervision to clinical staff and indirect guidance to other staff regarding clinical programming and treatment expectations to ensure effective & safe therapeutic practices are being provided. Leads all aspects of the outpatient counseling/social work programs including Psychosocial Assessments, conducting groups, facilitating family therapies, and developing, implementing, and reviewing Treatment Plans. Oversees all outpatient clinical programs, monitoring the multidisciplinary treatment team process, monitoring discharge planning, and community resource referral. Roles and Responsibilities: ESSENTIAL FUNCTIONS: Plans. develops and implements evidence-based quality programming including all clinical program schedules, as part of the therapeutic environment. Reviews the progress, quality, and effectiveness of all outpatient clinical programs. Identifies and prioritizes issues of importance, including those priority issues as set by leadership. Collaborates with department leaders and corporate leaders, as needed. Communicates instructions, expectations, and timelines clearly and concisely. Provides support and instruction as needed to direct care staff to ensure they adequately understand the treatment program and service delivery expectations to clients based on the clients' individual treatment plans and clinical needs. Ensures that all outpatient clinical programming, staffing, operations, and documentation is in accordance with regulatory agencies and standards of care.

### Associate Director, Market Access Analytics - Madrigal Pharmaceuticals Inc
- Location: 2 Locations (unspecified)
- Salary: $208K-$208K
- Posted: 2026-10-27
- 401(k) match: listed (not source-backed)
- Mental health support: yes (not source-backed)
- Apply: https://madrigalpharma.wd501.myworkdayjobs.com/Madrigal/job/PA---Conshohocken---Office/Associate-Director--Market-Access-Analytics_JR_000927
- Excerpt: Associate Director, Market Access Analytics 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Associate Director, Market Access Analytics leads payer, formulary, and coverage analytics for Madrigal's Commercial organization, turning access and contracting data into insight that guides Market Access strategy for the MASH portfolio. Reporting to the Senior Director, Market Access, Trade & IDN Analytics, this role owns the payer analytics and reporting agenda - measuring formulary access, coverage, utilization management, and contract performance at national and sub-national levels - and serves as a trusted analytics partner to Managed Markets, Patient

### Clinical Director- SUD - Summit BHC
- Location: Safe Harbor Recovery Center (unspecified)
- Salary: $115K-$120K
- Posted: 2026-11-02
- Apply: https://summitbhc.wd1.myworkdayjobs.com/Summit_BHC/job/Safe-Harbor-Recovery-Center/Clinical-Services-Director_JR127284
- Excerpt: Clinical Director- SUD Safe Harbor Recovery Center Clinical Director- SUD | Safe Harbor Recovery Center | Portsmouth, Virginia About the Job: Must be a LPC, LCSW, LMFT, or LSATP The Director of Clinical Services is responsible for the management and oversight of the day-to-day operations of the clinical department, planning, implementation, and evaluation of clinical care systems and for client health outcomes attributable to clinical practice. Provides direct supervision to clinical staff and indirect guidance to other staff regarding clinical programming and treatment expectations to ensure effective & safe therapeutic practices are being provided. Leads all aspects of the counseling/social work programs including Psychosocial Assessments, conducting groups, facilitating family therapies, and developing, implementing, and reviewing Treatment Plans. Oversees all clinical programs, monitoring the multidisciplinary treatment team process, monitoring discharge planning, and community resource referral. Roles and Responsibilities: Salary $115,000 - $120,000/year ESSENTIAL FUNCTIONS: Plans, develops and implements evidence-based quality programming including all clinical unit schedules, as part of the therapeutic environment. Reviews the progress, quality, and effectiveness of all clinical programs. Identifies and prioritizes issues of importance, including those priority issues as set by leadership. Collaborates with department leaders and corporate leaders, as needed. Communicates instructions, expectations, and timelines clearly and concisely. Provides support and instruction as needed to direct care staff to ensure they adequately understand the treatment program and service delivery expectations to clients based on the clients' individual treatment plans and clinical needs. Ensures that all clinical programming, staffing, and documentation is in accordance with regulatory agencies

### Senior Director, Global Market Access - Cogent Biosciences Inc
- Location: Waltham, Massachusetts, United States (unspecified)
- Salary: $260K-$305K
- Posted: 2026-09-29
- 401(k) match: listed (not source-backed)
- Learning budget: yes (not source-backed)
- Apply: https://job-boards.greenhouse.io/cogentbiosciences/jobs/4424700009
- Excerpt: Senior Director, Global Market Access Waltham, Massachusetts, United States Who We Are: Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has exhibited promising initial data across all three trials: APEX in AdvSM, SUMMIT in NonAdvSM and PEAK in GIST, including an encouraging safety profile across 600+ patients in single agent and combination dosing. The Role: Cogent Biosciences is seeking an entrepreneurial and strategic Senior Director, Global Market Access to develop and execute market access strategies that enable patients with cancer to access innovative therapies. Reporting to the Vice President, Value & Access Strategy, this role will have a global remit with some responsibility for the US market. The Sr. Director will work across the organization to translate clinical and economic value into compelling market access strategies across key markets. The role will partner closely with Commercial, Medical Affairs, Clinical Development, Regulatory, Finance, and other cross-functional teams, while working closely with the company's HEOR capabilities within the Value & Access organization to develop evidence and value strategies that support payer

### Occupational Therapist - FT - Summit BHC
- Location: Miramont Behavioral Health (unspecified)
- Salary: Not disclosed
- Posted: 2026-11-02
- Apply: https://summitbhc.wd1.myworkdayjobs.com/Summit_BHC/job/Miramont-Behavioral-Health/Occupational-Therapist---FT_JR127871
- Excerpt: Occupational Therapist - FT Miramont Behavioral Health Occupational Therapist - FT | Miramont Behavioral Health | Middleton, Wisconsin About the Job: PURPOSE STATEMENT: The Occupational Therapist treats patients who are recovering from injury, illness or disabled patients through the therapeutic use of everyday activities. Responsible for providing a comprehensive evaluation of performance components affecting Activities of Daily Living (ADL) functioning and providing goal-oriented treatment to facilitate maximum level of independence. Helps patients develop, recover and improve the skills needed for daily living and working. Roles and Responsibilities: ESSENTIAL FUNCTIONS: Reviews patient medical history, ask questions and observe patient's completing tasks to evaluate condition and needs. Develops a treatment plan for patients, identify specific goals and types of activities that will be used to help the patient work toward set goals. Plans and conducts group therapy and occasional individual sessions in accordance with the patient's treatment plan, program structures, department philosophy, and guidelines of Occupational Therapy practice. Helps people with various disabilities with different tasks, demonstrates exercises, evaluates a patient's home or workplace and based on the patient's health needs, identifies potential improvements. Educates a patient's family and employer about how to accommodate and care for the patient. Recommends special equipment, such as wheelchairs and eating aids and instructs patients on how to use that equipment. Maintains a consistent therapeutic milieu as outlined in hospital policy and procedures and according to program structures. Completes routine paperwork within the prescribed time frames; i.e., initial assessments, master treatment plans, progress notes, statistics, and

### Associate Director, Analytical Development - Cogent Biosciences Inc
- Location: Remote, United States (remote)
- Salary: $185K-$215K
- Posted: 2026-07-30
- 401(k) match: listed (not source-backed)
- Learning budget: yes (not source-backed)
- Apply: https://job-boards.greenhouse.io/cogentbiosciences/jobs/4341007009
- Excerpt: Associate Director, Analytical Development Remote, United States Who We Are: Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has exhibited promising initial data across all three trials: APEX in AdvSM, SUMMIT in NonAdvSM and PEAK in GIST, including an encouraging safety profile across 600+ patients in single agent and combination dosing. The Role: The Associate Director, Analytical Development, is responsible for leading analytical activities across Cogent's development portfolio and commercial product. This role within CMC will partner closely with Regulatory CMC, Quality, and external CDMOs to ensure analytical data, reports, methods, specifications, and regulatory-supporting documentation are accurate, phase-appropriate, and aligned with program objectives. The successful candidate will provide technical leadership in the review, interpretation, and communication of analytical results while ensuring high-quality documentation supports development, commercialization, and global regulatory submissions. Responsibilities: - Lead the preparation, review, and approval of analytical reports, data summaries, protocols, specifications, methods, and other CMC technical documentation. - Review analytical data packages supporting release testing, stability studies, drug substance, intermediates, and drug product manufacturing activities.

### Certified Recreational Therapist - Summit BHC
- Location: Willow Creek Behavioral Health (unspecified)
- Salary: Not disclosed
- Posted: 2026-10-28
- Apply: https://summitbhc.wd1.myworkdayjobs.com/Summit_BHC/job/Willow-Creek-Behavioral-Health/Certified-Recreational-Therapist-or-Occupational-Therapy-Assistant_JR127760
- Excerpt: Certified Recreational Therapist Willow Creek Behavioral Health Certified Recreational Therapist | Willow Creek Behavioral Health | Green Bay, Wisconsin About the Job: Schedule: M-F, 7:30AM - 4PM The Rec / Activity Therapist plans, organizes, and conducts comprehensive recreational therapy services as a component of the patient's treatment plan designed to assist the patient with learning healthy coping skills, strengths, hobbies, and assist with the development of social skills/relationships. Ensures all programming is consistent with accepted standards of practice and established policies and procedures. Roles and Responsibilities: ESSENTIAL FUNCTIONS: Performs patient assessments through patient/family interview, obtaining information on the patient's needs, skills, interests, strengths, and limitations for the development and implementation of individualized treatment plan. Plans and implements an activities program including but not limited to therapeutic leisure skills and activities, leisure education and leisure awareness to provide quality activities programs that meet patient needs and interests and helps the patient achieve his/her treatment goals. Coordinates patient activities while providing a safe environment. Orients patients to the activities program, explaining the benefits of the activities to the patients. Engages patients in therapeutic activities such as exercise, games sports, dance, music, art or relaxation techniques designed to meet their specific needs. Monitors and evaluates patient's progress, interest levels, attitude, and behaviors. Engages patients in individual and/or group recreation programming. Individual and group programming will fall under the five activity domains: physical, social, intellectual, creative and spiritual. Modifies activities to suit the needs of specific groups. Provides patients with activity resources, supplies and

### Director, Pipeline and Portfolio Market Planning - Corcept Therapeutics
- Location: Redwood City, California, United States (unspecified)
- Salary: $215K-$270K
- Posted: 2026-10-30
- 401(k) match: listed (not source-backed)
- Apply: https://www.corcept.com/careers/current-opportunities/?gh_jid=6240043004
- Excerpt: Director, Pipeline and Portfolio Market Planning Redwood City, California, United States For more than 25 years, Corcept has been singularly focused on the science of cortisol, a powerful hormone that when unregulated, can play a role in a broad range of diseases. Our commercial portfolio includes treatments for hypercortisolism and oncology, and the company has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. With advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease, Corcept is unlocking the power of cortisol modulation to help address some of the most devastating diseases patients face today. Corcept is headquartered in Redwood City, California. To learn more, visit www.corcept.com . The Director, Pipeline & Portfolio Market Planning is accountable for shaping and driving Corcept's oncology portfolio strategies. This leader will guide indication selection and sequencing, competitive landscape assessment, patient journey and treatment paradigm analysis, target product profile (TPP) development, product positioning, and long-range financial forecasting. The Director will serve as a key strategic partner to R&D, Commercial, and Senior Leadership, ensuring data-driven decisions that maximize the value and impact of Corcept's oncology investments. Responsibilities: - Drive and influence program-level strategy initiatives to define product vision, optimize lifecycle value, and drive business impact - Provide physician, patient, and payer perspective in clinical strategy and new product planning - Design, implement, and continuously refine competitive intelligence and market analysis frameworks that proactively inform program decision-making - Independently lead integrated cross-functional teams, including Commercial, Medical, Development, and Research, to

### Summit Suites Butler - Caesars Entertainment
- Location: South Lake Tahoe, NV, United States (unspecified)
- Salary: Not disclosed
- Posted: 2025-11-05
- 401(k) match: listed (not source-backed)
- Apply: https://edmn.fa.us2.oraclecloud.com/hcmUI/CandidateExperience/en/sites/CX_1/requisitions/job/75827
- Excerpt: Summit Suites Butler South Lake Tahoe, NV, United States This position provides Summit Suite guests with the finest in food, beverage, personal butler/valet services and amenities. Greets all Summit Suite guests upon arrival and explains facilities, services and attractions available for their comfort and pleasure. Serves meals, tea, hors d'oeuvres, cocktails and other food and beverage items in guests' suites. Works in conjunction with VIP Services and the Summit Chief Butler and to plan, organize and coordinate cocktail and dinner parties, receptions, entertainment and other special functions and services on request. Assists guests in unpacking, packing and the selection, care and maintenance of their wardrobe. Coordinates appropriate wardrobe needs, i.e., pressing, dry cleaning, and polishing shoes. In conjunction with VIP Services, arranges for personal services such as haircutting and styling, manicures, massages, etc. Remains immediately available during assigned shift to respond to guests' needs and expectations. Coordinates various services by notifying Summit Chief Butler/VIP Services of appropriate times to arrange cleaning, turn-down services, limousine arrangements, etc. Maintains stock of liquor and bar supplies, hors d'oeuvres, snacks and food items to meet guest needs. In conjunction with VIP Services, arranges for provision of special services on request such as birthday cakes, special food or beverages, room decorations, etc. Maintains butler pantry and all other assigned areas in a neat and serviceable condition. Reports any deficiencies to Chief Butler or manager, communicates and coordinates corrective action. Maintains confidentiality of all matters pertaining to our Summit Suite guests. Performs duties like washing/polishing silverware

### Sales Leader- New Jersey Summit Sales Territory - State Farm Mutual Automobile Insurance Company
- Location: Summit, New Jersey (unspecified)
- Salary: $200K-$310K
- Posted: 2026-10-30
- 401(k) match: listed (not source-backed)
- Apply: https://jobs.statefarm.com/jobs/43815?lang=en-us
- Excerpt: Sales Leader- New Jersey Summit Sales Territory Summit, New Jersey Overview Being good neighbors - helping people, investing in our communities, and making the world a better place - is who we are at State Farm. It is at the core of how we operate and the reason for our success. Come join a #1 team and do some good! Responsibilities Are you ready to drive impressive growth in a dynamic market? As our next Sales Leader, your primary purpose is to be the engine of territory growth. You will achieve this by leveraging comprehensive market knowledge and utilizing effective agent sales consulting to dramatically enhance the customer experience and meet diverse needs. This role is crucial for fostering a culture of high engagement and adaptability within the sales territory, helping to position our independent contractor agents to capture every bit of market potential. If you are passionate about leadership, growth, and building winning teams, we want to hear from you! In this job you are primarily responsible for: - Driving Territory Results : Using in-depth market knowledge and effective sales strategies to meet customer needs and deliver exceptional experiences - Business Coaching: Coaching agents on aspects of business management to evolve with customer demands and meet their business objectives - Agent Placement and Development: Overseeing the process of strategically placing and developing agents to maximize market opportunities Location: New Jersey Summit Sales Territory The Summit Sales Territory is based in Northern New Jersey and includes 54 Agents across Union,

### Sr. Clinical Trial Associate - Rapport Therapeutics Inc
- Location: 99 High Street, Suite 2100 , Boston, MA 02110 (unspecified)
- Salary: $90K-$110K
- Posted: 2026-08-12
- Apply: https://www.rapportrx.com/careers-board/?gh_jid=5194800007
- Excerpt: Sr. Clinical Trial Associate 99 High Street, Suite 2100 , Boston, MA 02110 When our people share why they joined Rapport and love it here, it comes down to three things: the science, the mission, and the team. At Rapport, we're driven by a passion for developing precision neuromedicines with the potential for fewer side effects, enabling patients and their families to enjoy healthier, more fulfilling lives. And we're doing this with extraordinary science and awesome people (affectionately called Rapptors). Our innovative scientific platform is centered on Receptor Associate Proteins (RAPs). RAPs are a component of neuronal receptor complexes, which play a crucial role in regulating receptor assembly and function. This precision approach has the potential to revolutionize the development of small molecule therapies. We are excited about the potential of our lead program, RAP-219. Our first indication targets focal epilepsy with additional clinical trials in primary generalized tonic-clonic seizures (PGTCS) and bipolar disorder. The strength of Rapport comes from our Rapptors - who are united by our mission to improve patients lives. We bring the heart and hustle to advance our science forward, always staying true to our core values. We hope you're as excited about this opportunity as we are! We anticipate hiring for this role in mid-Q4. This role is located in Boston, MA with an onsite requirement of Monday-Wednesday every week. Your impact: As a Senior Clinical Trial Associate, you'll be a key player in keeping our Bipolar Mania studies on track-managing the details, supporting the

### Financial Advisor - Summit Credit Union - LPL Financial
- Location: Waukesha WI (unspecified)
- Salary: Not disclosed
- Posted: 2026-10-19
- 401(k) match: listed (not source-backed)
- Apply: https://lplfinancial.wd1.myworkdayjobs.com/BD_Partners/job/Waukesha-WI/Financial-Advisor---Summit-Credit-Union_R-049722
- Excerpt: Financial Advisor - Summit Credit Union Waukesha WI Your career path should lead to real opportunity LPL Financial partners with TruStage to offer a complete menu of financial services to credit union clients. This employment opportunity at TruStage located at Summit Credit Union in Waukesha, WI would allow you to join Summit Credit Union as a Financial Advisor working for TruStage and associated with LPL Financial. Under this model Financial Advisors are not employees of LPL Financial. The Investment Program at Summit Credit Union supports the local community and you will be joining a team that is dedicated to helping members in every stage of their financial life. This exciting position will allow you to grow your career and business, helping the people and families that look to Summit Credit Union for financial solutions. This position will offer: The ability to service an existing book of business upon hire The ability to build a strong client base with the credit union's exceptional referral system Several branch territories with significant deposit base, which includes current members who need an advisor to support their financial goals The opportunity to find new clients via the credit union's member base The opportunity to create client solutions without proprietary products The ability to grow your business with LPL's combination of tools, technology, and support The benefit of LPL's experience helping financial institutions grow and maximize their investment programs The opportunity to capitalize on the credit union's reputation and community standing As an advisor associated with

---
Source-backed benefit claims include source links; other benefit values are labeled separately.